Meneldor

Overview

Meneldor is a Netherlands-based biopharmaceutical investment firm specializing in early-stage biotech and pharma companies. The firm focuses on companies that (re)develop new biological or chemical molecular entities, possess outstanding technology with strong intellectual property, address significant unmet medical needs, and operate in attractive markets. Meneldor primarily invests in projects that are in preclinical, Phase I, or Phase II stages, with a preference for indications with clear, well-defined clinical endpoints. The firm's geographic focus is Western Europe. Meneldor's investment strategy involves a thorough evaluation of potential portfolio companies, assessing aspects such as intellectual property, medical need, addressable markets, competition, risk, management, financial needs, and valuation. The firm manages the entire investment process, from selection to exit, including due diligence, regular reporting, administration, and syndicate building. Meneldor operates an open, flexible, evergreen investment model, where investors, through a Dutch cooperative, invest directly in a company. This approach allows Meneldor to negotiate favorable investment terms by bundling the financial power of several investors. The firm's portfolio includes investments in companies like Xenikos B.V., Atriva Therapeutics GmbH, The Aptamer Group Ltd, LightOx Ltd, and Tagworks Pharmaceuticals B.V. Meneldor's management is approachable and provides regular updates on major developments, ensuring transparency and active involvement in the growth of its portfolio companies.

Investment Focus

• Strong intellectual property
• Addressing significant unmet medical needs
• Operating in attractive markets
• Preclinical, Phase I, or Phase II stages
• Clear, well-defined clinical endpoints

Portfolio Companies